Their study, which will appear in the January 2010 issue of the International Journal of Tuberculosis and Lung Disease, is among the first to document the treatment of a patient with rifampin-dependent infection.
For the study, the research team documented the treatment of a 35-year-old Chinese man with tuberculosis. The man failed to respond to the WHO's thrice-weekly treatment regimen, which includes rifampin and other first-line tuberculosis drugs. The patient's condition worsened following an additional treatment regimen with rifampin and other second-line agents. Further testing detected the rifampin-dependency/enhancement. The patient fully recovered once rifampin was removed from his treatment regimen.
The World Health Organization (WHO) estimates that tuberculosis kills approximately 2 million people worldwide each year. Multidrug-resistant tuberculosis (MDR-TB) is becoming an increasing problem in many parts of the world, largely due to poor patient adherence to the six-month tuberculosis chemotherapy. About 5 percent of all TB cases are MDR-TB that is resistant to isoniazid and rifampin, two main drugs used to treat the disease.
"Rifampin-dependent tuberculosis is an unrecognized and potentially serious treatment issue," said Ying Zhang, MD, PhD, senior author of the study and professor in the Bloomberg School's W. Harry Feinstone Department of Molecular Microbiology and Immunology.
"Our study highlights the potential dangers of continued treatment of MDR-TB with rifamycins that occur frequently due to delayed or absent drug susceptibility testing in the field. Further studies are urgently needed to determine how common such rifampin-dependent MDR-TB is in field conditions and if it contributes to the worsening of the disease in MDR patients and treatment failures."
Zhang adds that rifampin-dependent tuberculosis is difficult to detect and may be a bigger problem than we currently realize, since the bacteria do not grow well in the culture medium unless rifampin is added.
The study authors urge timely detection of rifampin-dependent or -enhanced bacteria in patients with treatment failure by including rifampin in culture media and removing of rifampin from the treatment regimen once rifampin dependency or enhancement are detected. However, the researchers note that drug susceptibility testing is time-consuming and not easily performed in resource-poor settings where tuberculosis is frequently more common.
Citation: Zhong, M., Zhang, Wang, Zhang, Chen, G. Hu, P.2; Li M Zhu, Zhang W., Zhang Y., 'An interesting case of rifampicin-dependent/-enhanced multidrug-resistant tuberculosis', International Journal of Tuberculosis and Lung Disease, January 2010 , 14(1), 40-44
- Glycolipids Clue In How Tuberculosis Avoids Destruction Inside Cells
- The Lilly MDR-TB Partnership Provides Unique Model For Fight Against Multidrug-Resistant Tuberculosis In South Africa
- As HIV Has Evolved, Dolutegravin Has Become Less Effective In Sub-Saharan Africa
- New Vaccines Instead Of Antibiotics As Approach To Treating Infectious Diseases
- Ending Tuberculosis In Humans By Learning To Tolerate It